Colgate-Palmolive (NYSE:CL) Stock Position Increased by Smith Chas P & Associates PA Cpas

Smith Chas P & Associates PA Cpas grew its holdings in shares of Colgate-Palmolive (NYSE:CL) by 1.8% during the third quarter, HoldingsChannel.com reports. The institutional investor owned 18,503 shares of the company’s stock after purchasing an additional 323 shares during the quarter. Smith Chas P & Associates PA Cpas’ holdings in Colgate-Palmolive were worth $1,921,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently added to or reduced their stakes in the business. Diversify Advisory Services LLC bought a new position in Colgate-Palmolive during the first quarter valued at about $911,000. TD Asset Management Inc increased its stake in Colgate-Palmolive by 2.4% in the 1st quarter. TD Asset Management Inc now owns 1,154,566 shares of the company’s stock worth $103,969,000 after purchasing an additional 26,987 shares in the last quarter. Empowered Funds LLC increased its stake in Colgate-Palmolive by 277.3% in the 1st quarter. Empowered Funds LLC now owns 33,082 shares of the company’s stock worth $2,979,000 after purchasing an additional 24,314 shares in the last quarter. M&G Plc purchased a new stake in Colgate-Palmolive during the first quarter valued at about $3,812,000. Finally, Sei Investments Co. lifted its stake in Colgate-Palmolive by 41.5% during the first quarter. Sei Investments Co. now owns 598,639 shares of the company’s stock valued at $53,901,000 after buying an additional 175,445 shares in the last quarter. Institutional investors and hedge funds own 80.41% of the company’s stock.

Colgate-Palmolive Stock Up 0.9 %

Shares of CL stock opened at $100.10 on Monday. The stock has a market cap of $82.13 billion, a P/E ratio of 31.68, a price-to-earnings-growth ratio of 3.54 and a beta of 0.40. The company has a debt-to-equity ratio of 16.90, a current ratio of 1.06 and a quick ratio of 0.70. The stock has a fifty day moving average price of $103.56 and a 200 day moving average price of $97.25. Colgate-Palmolive has a one year low of $68.54 and a one year high of $109.30.

Colgate-Palmolive (NYSE:CL) last issued its earnings results on Friday, July 26th. The company reported $0.91 earnings per share for the quarter, beating the consensus estimate of $0.87 by $0.04. Colgate-Palmolive had a net margin of 14.21% and a return on equity of 470.19%. The business had revenue of $5.06 billion for the quarter, compared to analyst estimates of $5 billion. During the same period in the previous year, the business earned $0.77 EPS. The firm’s revenue was up 4.9% on a year-over-year basis. Analysts predict that Colgate-Palmolive will post 3.57 earnings per share for the current year.

Colgate-Palmolive Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, November 15th. Shareholders of record on Friday, October 18th will be paid a dividend of $0.50 per share. The ex-dividend date of this dividend is Friday, October 18th. This represents a $2.00 annualized dividend and a yield of 2.00%. Colgate-Palmolive’s dividend payout ratio is currently 63.29%.

Insider Buying and Selling at Colgate-Palmolive

In other Colgate-Palmolive news, Director Martina Hundmejean sold 2,313 shares of the company’s stock in a transaction dated Friday, August 23rd. The shares were sold at an average price of $103.86, for a total transaction of $240,228.18. Following the sale, the director now directly owns 11,755 shares of the company’s stock, valued at approximately $1,220,874.30. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other Colgate-Palmolive news, insider Sally Massey sold 15,850 shares of the stock in a transaction dated Tuesday, August 6th. The shares were sold at an average price of $103.28, for a total transaction of $1,636,988.00. Following the sale, the insider now owns 13,942 shares of the company’s stock, valued at $1,439,929.76. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Martina Hundmejean sold 2,313 shares of the business’s stock in a transaction dated Friday, August 23rd. The stock was sold at an average price of $103.86, for a total transaction of $240,228.18. Following the completion of the transaction, the director now directly owns 11,755 shares of the company’s stock, valued at approximately $1,220,874.30. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 43,490 shares of company stock valued at $4,486,063. 0.34% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

CL has been the subject of a number of research analyst reports. HSBC restated a “hold” rating on shares of Colgate-Palmolive in a report on Friday, July 26th. Stifel Nicolaus increased their price target on shares of Colgate-Palmolive from $95.00 to $105.00 and gave the stock a “buy” rating in a research report on Monday, July 22nd. Morgan Stanley boosted their price objective on shares of Colgate-Palmolive from $103.00 to $111.00 and gave the company an “overweight” rating in a research report on Monday, July 29th. Barclays increased their target price on shares of Colgate-Palmolive from $91.00 to $96.00 and gave the stock an “equal weight” rating in a research report on Monday, July 29th. Finally, Piper Sandler started coverage on shares of Colgate-Palmolive in a research note on Tuesday, September 24th. They issued an “overweight” rating and a $121.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and fourteen have assigned a buy rating to the company. According to data from MarketBeat.com, Colgate-Palmolive presently has a consensus rating of “Moderate Buy” and a consensus target price of $106.00.

Colgate-Palmolive Company Profile

Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products in the United States and internationally. It operates through two segments: Oral, Personal and Home Care; and Pet Nutrition. The Oral, Personal and Home Care segment offers toothpaste, toothbrushes, mouthwash, bar and liquid hand soaps, shower gels, shampoos, conditioners, deodorants and antiperspirants, skin health products, dishwashing detergents, fabric conditioners, household cleaners, and other related items.